Objective: Our study goal was evaluation of neuroinflammatory processes in patients with psychoses received  anti-psychotic medications and developed hyperkinesia or dystonia symptoms. Evaluation of pro-inflammatory cytokines and antibodies (AB) to neurotransmitters in course of anti-psychotic therapy showed necessity of application of specific immunomodulatory therapy in these cases.

Background: Neuroinflammation plays a substantial role in pathogenesis of number of movement disorders and organic brain psychoses and schizophrenia as well. Disbalance and AB to neurotransmitter’s receptors in patients with these diseases contribute in movement and psychiatry symptoms. In many cases,  anti-psychotic medications Halloperidol and Fluanxol used in psychiatry cause very often such  movement disorders like hyperkinesia and dystonia.

Method: Under our observation were 85 schizophrenia patients and 124 patients with organic brain psychoses (traumatic brain injury, brain tumors, senile dementias), men and women, from 26 to 84 years old. Control group comprised from 97 mentally and neurologically healthy donors by same ages and genders. Patients from both groups received combined treatment of Halloperidol and Fluanxol. AB to neurotransmitter’s receptors (dopamine, GABA, glutamate) and cytokines (IL 2, IL4, IL6, tumor necrosis factor (TNF) were detected by ELISA.

Results: After anti-psychotic treatmentб almost 84 percent of all patients developed some symptoms of movement disorders: hyperkinesia in form of chorea and atetosis in 51 per cent and dystonia affecting both the agonist muscle and opposing muscle in 33 per cent. It was revealed  dopamine AB were increased in 78 per cent of patients, GABA AB in 84 per cent, glutamate AB in 67 and serotonin AB in 91 per cent. Pro-inflammatory cytokines were increased in 76 per cent for IL2 and 85 per cent for IL6. During Halloperidol and Fluanxol therapy, hyperkinesia and dystonia symptoms were growing alongside with cytokines and AB increase.

Conclusion: Presence of anti-bodies to neurotransmitter’s receptors and pro-inflammatory cytokines in patients treated with anti-psychotic drugs and demonstrating hyperkinesia and dystonia symptoms require adding immunomodulatory medications to complex therapy of their conditions.We hypothesize tthese side effects could be predicted and alleviated by medications influencing brain neuroinflammatory reactions.

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/neuroinflammation-and-anti-psychotic-drugs-induced-hyperkinesia-or-dystonia-in-treatment-of-organic-brain-psychoses-and-schizophrenia/